The Comparison of the Necessity of Repeat Myocardial Perfusion SPECT Studies Between Tc-99m Tetro and Tc-99m Mibi
Study Details
Study Description
Brief Summary
Research Questions:
-
Is there a significant difference between the causal repeat rate of myocardial perfusion studies for Tc99m tetrofosmin and Tc99m sestamibi?
-
Is there a significant difference in the causal repeat rate of myocardial perfusion studies for Tc99m tetrofosmin and Tc99m sestamibi if an independent technologist reviewer blinded to the radiopharmaceutical makes the decision to repeat the study?
-
Is there a significant difference in the quantitative diagnostic measures reported between the original and the acceptable repeated studies?
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
|
Detailed Description
There are two commonly used Tc-99m based radiopharmaceuticals useful in the diagnosis and localization of regions of reversible myocardial ischemia in the presence or absence of infarction under exercise and rest conditions. One is Tc-99m tetrofosmin (Tc-99m-1,2-bis[bis(2-ethoxyethyl) phosphino] ethane), the other is Tc-99m sestamibi (Tc-99m- methoxyisobutylisonitrile). When performing a myocardial perfusion SPECT (MPS) study, extracardiac subdiaphragmatic activity adjacent to the myocardium can cause artifacts in the inferior wall and can be detrimental to the accuracy of the study1,2. Following acquisition, MPS studies are routinely checked for potential imaging artifacts. When a separation between the extracardiac activity cannot clearly be distinguished from the myocardium, the study should be repeated. Repeating the SPECT study can affect the efficiency of a lab as well as having a negative influence on patient comfort and overall satisfaction. The goal of this study is to determine if there is a significant difference in the number of studies that should be repeated between the two commonly used radiopharmaceuticals.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Tetrofosmin Rest patients Patients that had a Rest myocardial perfusion study using Tc99m tetrofosmin |
|
| Sestamibi stress patients Patients that had a stress myocardial perfusion imaging study using Tc99m Sestamibi |
|
| Tetrofosmin stress patients Patients that had a stress myocardial perfusion imaging study using Tc99m Tetrofosmin |
|
| Sestamibi rest patients Patients that had a rest myocardial perfusion imaging study using Tc99m Sestamibi |
Outcome Measures
Primary Outcome Measures
- Number of studies repeated. [four weeks]
Secondary Outcome Measures
- Number of studies that should have been repeated [two weeks after data collection]
Eligibility Criteria
Criteria
Inclusion Criteria:
- Patients receiving sestamibi MPI study or tetrofosmin MPI study
Exclusion Criteria:
- Thallium or dual isotope MPI study
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Cardiac Imaging of Augusta | Augusta | Georgia | United States | 30901 |
Sponsors and Collaborators
- Cardiac Imaging of Augusta
- GE Healthcare
Investigators
- Study Director: Danny A Basso, CNMT, Cardiac Imaging of Augusta
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- DB1